Study Finds Maribavir And Valganciclovir Linked To Comparable Viremia Clearance Rates Among Patients With Asymptomatic CMV Infection Following HSCT

Infectious Disease Advisor (1/25, Chan) reports, “Study findings published in Clinical Infectious Diseases indicate that maribavir and valganciclovir are associated with comparable rates of viremia clearance among patients with asymptomatic cytomegalovirus (CMV) infection following hematopoietic stem cell transplantation (HSCT).” In the study, “at week 8, 69.9% of patients in the maribavir group and 77.4% of those in the valganciclovir achieved CMV viremia clearance. However, noninferiority of maribavir to valganciclovir was not achieved.”